Clinical trials: PD-L1
Hepatocellular Carcinoma (HCC)
Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab
To evaluate the efficacy and safety of Tauroursodeoxycholic Acid (TUDCA) plus Camrelizumab and Regorafenib for patients with advanced hepatocellular carcinoma (HCC) who have progressed on prior systemic treatment with…
- Trial name
- LEAF-02 (NCT07100392)
- Testing
- tauroursodeoxycholic acid (TUDCA), Camrelizumab, Regorafenib
- Where
- China
- Volunteers
- 141 people
- Sponsor
- Fudan University
Recurrent Head and Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma
Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma
This is a phase 2 study investigating the efficacy of ramucirumab in combination with pembrolizumab compared to pembrolizumab monotherapy.
- Conditions
- Recurrent Head and Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma
- Trial name
- Rambro2 (NCT05980000)
- Testing
- Ramucirumab, Pembrolizumab
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Washington University School of Medicine
Non-small Cell Lung Cancer Stage III, PDL1 Gene Mutation
Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients
Observational, multicenter, one-arm, non-comparative study. Data will be recorded in a retrospectively manner. The study will be based on secondary data collected from patient clinical chart completed by the doctor during routine…
- Trial name
- SIENNA (NCT06634199)
- Testing
- Durvalumab
- Where
- 22 sites in Spain
- Volunteers
- 50 people
- Sponsor
- Fundación GECP
Head and Neck Squamous Cell Carcinoma
Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01
Master protocol: The main goal of this master clinical study is to evaluate the efficacy and safety of multiple novel combination therapies in participants with head and neck squamous cell carcinoma (HNSCC) in various substudies.
- Trial name
- VELOCITY-HNSCC (NCT06727565)
- Testing
- Domvanalimab, Zimberelimab, Paclitaxel
- Where
- 23 sites in United States, Australia and 7 more
- Volunteers
- 39 people
- Sponsor
- Gilead Sciences
Esophageal Neoplasms
First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension Study
The purpose of this Chinese extension study is to evaluate efficacy and safety of pembrolizumab plus cisplatin and 5-fluorouracil (5-FU) chemotherapy versus placebo plus cisplatin and 5-FU chemotherapy as first-line treatment in…
- Trial name
- NCT03881111
- Testing
- Pembrolizumab, Cisplatin, 5-FU
- Where
- 20 sites in China
- Sponsor
- Merck Sharp & Dohme LLC
Multiple Myeloma
Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)
The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) in combination with daratumumab in participants with relapsed refractory multiple myeloma (rrMM).
- Trial name
- NCT03221634
- Testing
- Pembrolizumab, Daratumumab
- Where
- 23 sites in United States, Canada and 4 more
- Sponsor
- Merck Sharp & Dohme LLC
Locally Advanced Cervical Cancer
Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab
The primary objective of this randomized phase II trial is to evaluate the clinical benefits of the addition of atezolizumab to standard chemoradiotherapy (CRT) (first given concurrently with CRT, then continued as adjuvant…
- Trial name
- ATEZOLACC (NCT03612791)
- Testing
- Atezolizumab, Radiotherapy, Cisplatin
- Where
- France
- Volunteers
- 189 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Non-Small Cell Lung Cancer
A Translational Study Investigating PD-L1 Expression After Radiotherapy for Non-small Cell Lung Cancer
Participants with Non-Small Cell Lung Cancer (NSCLC), Performance Status (PS) 0-2, not suitable for concurrent Chemo-Radiotherapy (CTRT), will be treated with standard radiotherapy (radical or palliative).
- Trial name
- PD-RAD (NCT03258788)
- Testing
- Biopsy and blood samples
- Where
- 3 sites in United Kingdom
- Volunteers
- 15 people
- Sponsor
- The Christie NHS Foundation Trust
Metastatic Non Small Cell Lung Cancer
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer
- Trial name
- NCT04614103
- Testing
- LN-145
- Where
- 71 sites in United States, Australia and 10 more
- Volunteers
- 170 people
- Sponsor
- Iovance Biotherapeutics, Inc.
Carcinoma, Non-Small-Cell Lung, Drug-Related Side Effects and Adverse Reactions
Side Effects of Anti-PD-(L)-1 and Anti CTLA-A4 in the Non Small Cells Lung Cancer
The immune-related adverse events (irAEs) linked to the important activation of the immune system by new immunotherapy treatments in patients affected by Non-small-cell lung carcinoma (NSCLC) have not received a lot of systematic…
- Trial name
- NCT03125603
- Testing
- Consultation of the patient's medical files at the hospital
- Where
- Belgium
- Volunteers
- 80 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Triple Negative Breast Neoplasms
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC).
- Trial name
- NCT06841354
- Testing
- Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication
- Where
- 283 sites in United States, Argentina and 33 more
- Volunteers
- 1,000 people
- Sponsor
- Merck Sharp & Dohme LLC
Malignant Melanoma
A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma
This is an open-label, multicenter, Phase Ib, dose-escalation and cohort-expansion study of atezolizumab (anti-programmed death-ligand 1 [PD-L1] antibody) in combination with vemurafenib or vemurafenib plus cobimetinib in…
- Trial name
- NCT01656642
- Testing
- Atezolizumab, Cobimetinib, Vemurafenib
- Where
- 8 sites in United States
- Volunteers
- 67 people
- Sponsor
- Genentech, Inc.
Advanced Cancer, Metastatic Cancer
A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies
This study will be conducted in adult participants diagnosed with advanced tumors to characterize the safety, tolerability, pharmacokinetics (PK), and activity of FS118.
- Conditions
- Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT03440437
- Testing
- FS118, Paclitaxel
- Where
- 12 sites in United States, France
- Volunteers
- 80 people
- Sponsor
- invoX Pharma Limited
HNSCC, DNA Damage
Predictive Biomarkers for Response to Nivolumab in Head and Neck Squamous Cell Carcinoma
Nivolumab is FDA-approved for the treatment of patients with recurrent/metastatic Head and Neck Squamous Cell Carcinoma (HNSCC). HNSCC whose disease has progressed within 6 months after platinum-based chemotherapy.
- Conditions
- HNSCC, DNA Damage, DNA Double Strand Break
- Trial name
- NCT03652142
- Testing
- Biomarker Research, Nivolumab
- Where
- Greece
- Volunteers
- 50 people
- Sponsor
- Attikon Hospital
Lung Cancer
ANALYSIS OF INFLAMMATORY REACTIONS OBSERVED IN BRONCHOALVEOLAR LAVAGES (BALS)
Immunological toxicities associated with immune checkpoint inhibitor (ICI) monoclonal antibodies are unpredictable autoimmune and inflammatory pathologies that can affect all treated patients.
- Trial name
- LBA-PI (NCT05117372)
- Testing
- treatment with immunotherapy and diffuse infiltrative lung disease, Patients requiring carcinologic lobectomy
- Where
- France
- Volunteers
- 34 people
- Sponsor
- Centre Chirurgical Marie Lannelongue
Extensive-Stage Small Cell Lung Cancer
Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC
This is a Phase II, single-arm, open-label clinical study to evaluate the efficacy and safety of Sacituzumab Tirumotecan (SKB264) combined with Anlotinib in patients with extensive-stage small cell lung cancer (ES-SCLC).
- Trial name
- SKB264-ANLO (NCT07388875)
- Testing
- Sacituzumab Tirumotecan, Anlotinib
- Volunteers
- 30 people
- Sponsor
- China Medical University, China
Hodgkins Lymphoma
Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS)
This is a Phase 1b, open-label, multi-center study comprising a lead-in phase and an expansion phase. The lead-in phase is a multiple-dose, randomized, parallel-arm, pharmacokinetic and pharmacodynamic study of avelumab as a…
- Trial name
- NCT02603419
- Testing
- Avelumab
- Where
- 13 sites in United States, Italy and 1 more
- Volunteers
- 34 people
- Sponsor
- Pfizer
Triple Negative Breast Neoplasms, Triple Negative Breast Cancer
Triple-negative Breast Cancer: a New Perspective on Biomarkers
A single-institutional cohort to determine the prevalence of new immunohistochemical panel in advanced triple-negative submitted to neoadjuvant chemotherapy and its association with response and survival.
- Trial name
- TNBCbrazil (NCT03539965)
- Where
- Brazil
- Volunteers
- 239 people
- Sponsor
- Instituto Nacional de Cancer, Brazil
Head/Neck Neoplasm
IT or IA Infusion of PD1/PDL1/CTLA4 Inhibitors Versus IV for Immunotherapy of Head/Neck Cancers (HNC)
This trial was designed to investigate the survival outcomes, response rates, and safety of patients with advanced Head/Neck Squamous cancer via intra-tumor or intra-artery versus vein infusion of PD1/PDL1/CTLA4 inhibitor or…
- Trial name
- NCT03952065
- Testing
- PD1/PDL1/CTLA4 inhibitors
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Testicular Neoplasms, Neoplasms, Germ Cell and Embryonal
Avelumab in Refractory Testicular Germ Cell Cancer.
This is a proof-of-concept study to define efficacy of AVELUMAB in patients with multiple relapsed/refractory germ cell tumors (GCTs).
- Conditions
- Testicular Neoplasms, Neoplasms, Germ Cell and Embryonal, Neoplasms, Testicular Diseases
- Trial name
- NCT03403777
- Testing
- Avelumab
- Where
- Slovakia
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute, Slovakia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.